Literature DB >> 15180328

Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2.

Masakazu Hirouchi1, Hiroshi Suzuki, Masaya Itoda, Shogo Ozawa, Jun-ichi Sawada, Ichiro Ieiri, Kenji Ohtsubo, Yuichi Sugiyama.   

Abstract

PURPOSE: The presence of single nucleotide polymorphisms (SNPs) has been reported for multidrug resistance-associated protein 2 (MRP2/ABCC2). The purpose of the current study was to characterize the localization, expression level, and function of MRP2 variants.
METHODS: The expression and cellular localization of the wild-type and three kinds of reported SNP variants of MRP2 molecules were analyzed in LLC-PK1 cells after infection with the recombinant Tet-off adenoviruses. Their function was determined by using the isolated membrane vesicles from the infected LLC-PK1 cells.
RESULTS: The transport activity for E217betaG, LTC4, and DNP-SG, normalized by the expression level of MRP2, was similar between the wild-type, V417I, and A1450T MRP2s. The transport activity of S789F MRP2 was slightly higher than that of wild-type MRP2. However, the expression level of S789F and A1450T MRP2 proteins was significantly lower compared with the wild-type and V417I MRP2. In addition, although the wild-type and V417I MRP2 were exclusively localized in the apical membrane, S789F and A1450T MRP2 were located in the apical membrane and also in the intracellular compartment.
CONCLUSIONS: These results suggest that the most frequently observed V417I substitution may not affect the in vivo function of MRP2, whereas the much less frequently observed S789F and A1450T may be associated with the reduced in vivo function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15180328     DOI: 10.1023/b:pham.0000026422.06207.33

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  30 in total

1.  Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats.

Authors:  C G Dietrich; D R de Waart; R Ottenhoff; I G Schoots; R P Elferink
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

2.  Charged amino acids in the transmembrane domains are involved in the determination of the substrate specificity of rat Mrp2.

Authors:  K Ito; H Suzuki; Y Sugiyama
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

3.  Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans.

Authors:  R G Tirona; B F Leake; G Merino; R B Kim
Journal:  J Biol Chem       Date:  2001-07-26       Impact factor: 5.157

4.  Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects.

Authors:  S Ito; I Ieiri; M Tanabe; A Suzuki; S Higuchi; K Otsubo
Journal:  Pharmacogenetics       Date:  2001-03

Review 5.  Hepatic secretion of conjugated drugs and endogenous substances.

Authors:  D Keppler; J König
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

Review 6.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors:  J A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

7.  Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome.

Authors:  M Wada; S Toh; K Taniguchi; T Nakamura; T Uchiumi; K Kohno; I Yoshida; A Kimura; S Sakisaka; Y Adachi; M Kuwano
Journal:  Hum Mol Genet       Date:  1998-02       Impact factor: 6.150

Review 8.  The drug efflux pump MRP2: regulation of expression in physiopathological situations and by endogenous and exogenous compounds.

Authors:  L Payen; L Sparfel; A Courtois; L Vernhet; A Guillouzo; O Fardel
Journal:  Cell Biol Toxicol       Date:  2002       Impact factor: 6.691

9.  Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis.

Authors:  Takashi Nozawa; Miki Nakajima; Ikumi Tamai; Kumiko Noda; Jun-Ichi Nezu; Yoshimichi Sai; Akira Tsuji; Tsuyoshi Yokoi
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

10.  Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membranes.

Authors:  K Kobayashi; Y Sogame; H Hara; K Hayashi
Journal:  J Biol Chem       Date:  1990-05-15       Impact factor: 5.157

View more
  25 in total

Review 1.  Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.

Authors:  Tristan M Sissung; Sarah M Troutman; Tessa J Campbell; Heather M Pressler; Hyeyoung Sung; Susan E Bates; William D Figg
Journal:  Discov Med       Date:  2012-01       Impact factor: 2.970

2.  In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants.

Authors:  Xia Wen; Melanie S Joy; Lauren M Aleksunes
Journal:  Pharm Res       Date:  2017-04-12       Impact factor: 4.200

Review 3.  The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.

Authors:  Nicolas Picard; Pierre Marquet
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-03-25       Impact factor: 4.481

4.  Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions.

Authors:  N Božina; Z Lalić; S Nađ-Škegro; A Borić-Bilušić; T Božina; Ž Kaštelan; V Trkulja
Journal:  Eur J Clin Pharmacol       Date:  2017-06-18       Impact factor: 2.953

5.  Treatment of hyperbilirubinemia in Eisai hyperbilirubinemic rat by transfecting human MRP2/ABCC2 gene.

Authors:  Masakazu Hirouchi; Hiroshi Suzuki; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

6.  Report of new haplotype for ABCC2 gene: rs17222723 and rs8187718 in cis.

Authors:  Victoria M Pratt; Brittany N Beyer; Daniel L Koller; Todd C Skaar; David A Flockhart; Kenneth D Levy; Gail H Vance
Journal:  J Mol Diagn       Date:  2014-12-29       Impact factor: 5.568

7.  Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2).

Authors:  Vandana Megaraj; Tianyong Zhao; Christian M Paumi; Phillip M Gerk; Richard B Kim; Mary Vore
Journal:  Pharmacogenet Genomics       Date:  2011-08       Impact factor: 2.089

8.  Association of CYP2C9*2 with bosentan-induced liver injury.

Authors:  S M Markova; T De Marco; N Bendjilali; E A Kobashigawa; J Mefford; J Sodhi; H Le; C Zhang; J Halladay; A E Rettie; C Khojasteh; D McGlothlin; A H B Wu; W-C Hsueh; J S Witte; J B Schwartz; D L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2013-07-17       Impact factor: 6.875

9.  The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene.

Authors:  Nada Abla; Leslie W Chinn; Tsutomu Nakamura; Li Liu; Conrad C Huang; Susan J Johns; Michiko Kawamoto; Doug Stryke; Travis R Taylor; Thomas E Ferrin; Kathleen M Giacomini; Deanna L Kroetz
Journal:  J Pharmacol Exp Ther       Date:  2008-03-25       Impact factor: 4.030

10.  Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants.

Authors:  Richard H Ho; Leena Choi; Wooin Lee; Gail Mayo; Ute I Schwarz; Rommel G Tirona; David G Bailey; C Michael Stein; Richard B Kim
Journal:  Pharmacogenet Genomics       Date:  2007-08       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.